Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 203
Filtrar
1.
Crit Care Med ; 51(8): 1064-1073, 2023 Aug 01.
Artículo en Inglés | MEDLINE | ID: covidwho-20235834

RESUMEN

OBJECTIVES: Early studies of venovenous extracorporeal membrane oxygenation (ECMO) in COVID-19 have revealed similar outcomes to historical cohorts. Changes in the disease and treatments have led to differences in the patients supported on venovenous ECMO in the first and second waves. We aimed to compare these two groups in both the acute and follow-up phase. DESIGN: Retrospective single-center cohort study comparing mortality at censoring date (November 30, 2021) and decannulation, patient characteristics, complications and lung function and quality of life (QOL-by European Quality of Life 5 Dimensions 3 Level Version) at first follow-up in patients supported on venovenous ECMO between wave 1 and wave 2 of the COVID-19 pandemic. SETTING: Critical care department of a severe acute respiratory failure service. PATIENTS: Patients supported on ECMO for COVID-19 between wave 1 (March 17, 2020, to August 31, 2020) and wave 2 (January 9, 2020, to May 25, 2021). INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: One hundred twenty-three patients were included in our analysis. Survival at censoring date (χ 2 , 6.35; p = 0.012) and decannulation (90.4% vs 70.0%; p < 0.001) was significantly lower in the second wave, while duration of ECMO run was longer (12.0 d [18.0-30.0 d] vs 29.5 d [15.5-58.3 d]; p = 0.005). Wave 2 patients had longer application of noninvasive ventilation (NIV) prior to ECMO and a higher frequency of barotrauma. Patient age and NIV use were independently associated with increased mortality (odds ratio 1.07 [1.01-1.14]; p = 0.025 and 3.37 [1.12-12.60]; p = 0.043, respectively). QOL and lung function apart from transfer coefficient of carbon monoxide corrected for hemoglobin was similar at follow-up across the waves. CONCLUSIONS: Most patients with COVID-19 supported on ECMO in both waves survived in the short and longer term. At follow-up patients had similar lung function and QOL across the two waves. This suggests that ECMO has an ongoing role in the management of a carefully selected group of patients with COVID-19.


Asunto(s)
COVID-19 , Oxigenación por Membrana Extracorpórea , Humanos , COVID-19/terapia , Oxigenación por Membrana Extracorpórea/métodos , Calidad de Vida , Estudios de Cohortes , Estudios Retrospectivos , Pandemias
2.
ASAIO J ; 69(5): e188-e191, 2023 05 01.
Artículo en Inglés | MEDLINE | ID: covidwho-2327633

RESUMEN

Veno-venous extracorporeal membrane oxygenation (VV ECMO) is used as a treatment modality in those who fail to respond to conventional care. Hypoxia and medications used in the intensive care unit may increase risk for atrial arrhythmias (AA). This study aims to evaluate the impact of AA on post-VV ECMO outcome. A retrospective review of patients who were placed on VV ECMO between October 2016 and October 2021. One hundred forty-five patients were divided into two groups, AA and no AA. Baseline characteristic and potential risk factors were assessed. Uni- and multivariate analysis using logistic regression models were constructed to evaluate the predictors of mortality between groups. Survival between groups was estimated by the Kaplan-Meier method using the log-rank test. Advanced age with history of coronary artery disease and hypertension were associated with increased risk to develop AA post-VV ECMO placement ( p value < 0.05). Length on ECMO, time intubated, hospital length of stay, and sepsis were significantly increased in patients in the AA group ( p value < 0.05). There was no difference in the overall mortality between the two groups. AAs were associated with worse hospital course and complications but no difference in overall mortality rate. Age and cardiovascular disease seem to be predisposing risk factors for this. Further studies are needed to investigate potential strategies to prevent AAs development in this population.


Asunto(s)
Fibrilación Atrial , Oxigenación por Membrana Extracorpórea , Humanos , Oxigenación por Membrana Extracorpórea/métodos , Estudios Retrospectivos , Factores de Riesgo , Análisis Multivariante
4.
Semin Cardiothorac Vasc Anesth ; 27(2): 87-96, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: covidwho-2312335

RESUMEN

The past year in critical care medicine was notable for ongoing sequelae of the COVID-19 pandemic, including nationwide shortages and critical care demand in many regions in excess of usual operating capacity. Despite these challenges, evidence-based medicine and investigations into the optimal management of the critically ill continued to be at the forefront. This article is a collection of studies published in 2022 which are specifically relevant to cardiothoracic critical care. These noteworthy publications add to the existing literature across a broad spectrum of topics, from optimal timing of mechanical circulatory support (MCS), delirium prevention, updates in nutrition guidelines, alternative defibrillation techniques, novel ventilator management, and observing the downstream psychological impact of extracorporeal membrane oxygenation (ECMO) therapy.


Asunto(s)
COVID-19 , Oxigenación por Membrana Extracorpórea , Humanos , Pandemias , COVID-19/terapia , Cuidados Críticos/métodos , Oxigenación por Membrana Extracorpórea/métodos , Progresión de la Enfermedad , Enfermedad Crítica/terapia
5.
Perfusion ; 38(1_suppl): 40-43, 2023 05.
Artículo en Inglés | MEDLINE | ID: covidwho-2318599

RESUMEN

Patients with extracorporeal membrane oxygenation (ECMO) support do frequently receive broad-spectrum antibiotics, due to the high frequency of infection by multidrug resistant microorganisms. The extracorporeal circuit can alter the pharmacokinetics (PK) of administered drugs, and in the case of antibiotics this may lead to treatment failure. Cefiderocol is a new cephalosporin that exhibits excellent in vitro activity against many multidrug-resistant (MDR) microorganisms, but there is no published data about the modifications of its PK in patients with ECMO support. Herein we report the results of a pharmacokinetic investigation of cefiderocol in a critically ill patient receiving extracorporeal respiratory support.


Asunto(s)
Oxigenación por Membrana Extracorpórea , Humanos , Oxigenación por Membrana Extracorpórea/métodos , Antibacterianos/uso terapéutico , Cefalosporinas/uso terapéutico , Monobactamas
6.
J Cardiothorac Surg ; 18(1): 134, 2023 Apr 11.
Artículo en Inglés | MEDLINE | ID: covidwho-2305068

RESUMEN

COVID-19 infection can lead to severe acute respiratory distress syndrome (ARDS), right ventricular (RV) failure and pulmonary hypertension. Venovenous extracorporeal membrane oxygenation (V-V ECMO) has been used for patients with refractory hypoxemia. More recently dual-lumen right atrium to pulmonary artery oxygenated right ventricular assist devices (Oxy-RVAD) have been utilized in the severe medical refractory COVID ARDS setting. Historically, animal data has demonstrated that high continuous non-pulsatile RVAD flows, leading to unregulated and unprotected circulation through the pulmonary vessels is associated with an increased risk of pulmonary hemorrhage and increased amount of extravascular lung water. These risks are heightened in the setting of ARDS with fragile capillaries, left ventricular (LV) diastolic failure, COVID cardiomyopathy, and anticoagulation. Concurrently, due to infection, tachycardia, and refractory hypoxemia, high V-V ECMO flows to match high cardiac output are often necessary to maintain systemic oxygenation. Increase in cardiac output without a concurrent increase in VV ECMO flow will result in a higher fraction of deoxygenated blood returning to the right heart and therefore resulting in hypoxemia. Several groups have suggested using a RVAD only strategy in COVID ARDS; however, this exposes the patients to the risk of pulmonary hemorrhage. We present one of the first known cases using an RV mechanical support, partial flow pulmonary circulation, oxygenated Veno-venopulmonary (V-VP) strategy resulting in RV recovery, total renal recovery, awake rehabilitation, and recovery.


Asunto(s)
COVID-19 , Oxigenación por Membrana Extracorpórea , Insuficiencia Cardíaca , Corazón Auxiliar , Síndrome de Dificultad Respiratoria , Animales , Oxigenación por Membrana Extracorpórea/métodos , Resultado del Tratamiento , Ventrículos Cardíacos , Insuficiencia Cardíaca/etiología , Síndrome de Dificultad Respiratoria/etiología , Hipoxia/etiología
7.
Int J Numer Method Biomed Eng ; 39(6): e3706, 2023 06.
Artículo en Inglés | MEDLINE | ID: covidwho-2290710

RESUMEN

Extra corporeal membrane oxygenation (ECMO) is an artificial oxygenation facility, employed in situations of cardio-pulmonary failure. Some diseases i.e., acute respiratory distress syndrome, pulmonary hypertension, corona virus disease (COVID-19) etc. affect oxygenation performance of the lungs thus requiring the need of artificial oxygenation. Critical care teams used ECMO technique during the COVID-19 pandemic to support the heart and lungs of COVID-19 patients who had an acute respiratory or cardiac failure. Double Lumen Cannula (DLC) is one of the most critical components of ECMO as it resides inside the patient and, connects patient with external oxygenation circuit. DLC facilitates delivery and drainage of blood from the patient's body. DLC is characterized by delicate balance of internal and external flows inside a limited space of the right atrium (RA). An optimal performance of the DLC necessitates structural stability under biological and hemodynamic loads, a fact that has been overlooked by previously published studies. In the past, many researchers experimentally and computationally investigated the hemodynamic performance of DLC by employing Eulerian approach, which evaluate instantaneous blood damage without considering blood shear exposure history (qualitative assessment only). The present study is an attempt to address the aforementioned limitations of the previous studies by employing Lagrangian (quantitative assessment) and incorporating the effect of fluid-structure interaction (FSI) to study the hemodynamic performance of neonatal DLC. The study was performed by solving three-dimensional continuity, momentum, and structural mechanics equation(s) by numerical methods for the blood flow through neonatal DLC. A two-way coupled FSI analysis was performed to analyze the effect of DLC structural deformation on its hemodynamic performance. Results show that the return lumen was the most critical section with maximum pressure drop, velocity, shear stresses, and blood damage. Recirculation and residence time of blood in the right atrium (RA) increases with increasing blood flow rates. Considering the structural deformation has led to higher blood damage inside the DLC-atrium system. Maximum Von-Mises stress was present on the side edges of the return lumen that showed direct proportionality with the blood flow rate.


Asunto(s)
COVID-19 , Oxigenación por Membrana Extracorpórea , Recién Nacido , Humanos , Oxigenación por Membrana Extracorpórea/métodos , Cánula , Pandemias , Hemodinámica/fisiología
8.
J Thorac Cardiovasc Surg ; 165(1): 301-326, 2023 01.
Artículo en Inglés | MEDLINE | ID: covidwho-2262335

RESUMEN

OBJECTIVE: The use of mechanical circulatory support (MCS) in lung transplantation has been steadily increasing over the prior decade, with evolving strategies for incorporating support in the preoperative, intraoperative, and postoperative settings. There is significant practice variability in the use of these techniques, however, and relatively limited data to help establish institutional protocols. The objective of the AATS Clinical Practice Standards Committee (CPSC) expert panel was to review the existing literature and establish recommendations about the use of MCS before, during, and after lung transplantation. METHODS: The AATS CPSC assembled an expert panel of 16 lung transplantation physicians who developed a consensus document of recommendations. The panel was broken into subgroups focused on preoperative, intraoperative, and postoperative support, and each subgroup performed a focused literature review. These subgroups formulated recommendation statements for each subtopic, which were evaluated by the entire group. The statements were then developed via discussion among the panel and refined until consensus was achieved on each statement. RESULTS: The expert panel achieved consensus on 36 recommendations for how and when to use MCS in lung transplantation. These recommendations included the use of veno-venous extracorporeal membrane oxygenation (ECMO) as a bridging strategy in the preoperative setting, a preference for central veno-arterial ECMO over traditional cardiopulmonary bypass during the transplantation procedure, and the benefit of supporting selected patients with MCS postoperatively. CONCLUSIONS: Achieving optimal results in lung transplantation requires the use of a wide range of strategies. MCS provides an important mechanism for helping these critically ill patients through the peritransplantation period. Despite the complex nature of the decision making process in the treatment of these patients, the expert panel was able to achieve consensus on 36 recommendations. These recommendations should provide guidance for professionals involved in the care of end-stage lung disease patients considered for transplantation.


Asunto(s)
Oxigenación por Membrana Extracorpórea , Trasplante de Pulmón , Cirugía Torácica , Procedimientos Quirúrgicos Torácicos , Humanos , Consenso , Trasplante de Pulmón/efectos adversos , Trasplante de Pulmón/métodos , Procedimientos Quirúrgicos Torácicos/métodos , Oxigenación por Membrana Extracorpórea/efectos adversos , Oxigenación por Membrana Extracorpórea/métodos
9.
Int J Artif Organs ; 46(4): 248-251, 2023 Apr.
Artículo en Inglés | MEDLINE | ID: covidwho-2267646

RESUMEN

At the beginning of the COVID-19 pandemic, the role of extracorporeal membrane oxygenation (ECMO) was uncertain and the outcomes of ECMO-treated patients were unfavorable. During the pandemic, medical community realized that carefully selected patients may benefit from ECMO support. The goal of the study was to present the outcomes of ECMO-treated patients with severe COVID-19 ARDS referred to the respiratory ECMO hub in Croatia and to determine variables that influenced the outcome. Our study included all adult patients with confirmed COVID-19 ARDS that required ECMO treatment, in the period between February 2020 and April 2022. All ECMO circuits were veno-venous with femoro-jugular configuration, with drainage at the femoral site. A total of 112 adult patients with COVID-19 induced ARDS were included in the study. All patients had veno-venous ECMO treatment and 34 survived. Surviving patients were discharged home either from the hospital or from a designated rehabilitation facility. The mortality was associated with the incidence of nosocomial bacteremia, occurrence of heparin induced thrombocytopenia and acute renal failure. In order to reduce the mortality in COVID-19 ECMO patients, the treatment should be started as soon as criteria for ECMO are met. Furthermore, complications of the procedure should be detected as soon as possible. However, despite even the optimal approach, the mortality in COVID-19 ECMO patients will surpass that of non-COVID-19 ARDS ECMO patients, mostly due to poor resolving and long lasting ARDS with longer ECMO runs and ensuing infectious complications.


Asunto(s)
COVID-19 , Oxigenación por Membrana Extracorpórea , Síndrome de Dificultad Respiratoria , Adulto , Humanos , COVID-19/terapia , Oxigenación por Membrana Extracorpórea/efectos adversos , Oxigenación por Membrana Extracorpórea/métodos , Croacia/epidemiología , Pandemias , Derivación y Consulta , Síndrome de Dificultad Respiratoria/etiología , Síndrome de Dificultad Respiratoria/terapia
10.
Clin Chest Med ; 44(2): 335-346, 2023 06.
Artículo en Inglés | MEDLINE | ID: covidwho-2275611

RESUMEN

The coronavirus disease 2019 (COVID-19) pandemic has seen an increase in global cases of severe acute respiratory distress syndrome (ARDS), with a concomitant increased demand for extracorporeal membrane oxygenation (ECMO). Outcomes of patients with severe ARDS due to COVID-19 infection receiving ECMO support are evolving. The need for surge capacity, practical and ethical limitations on implementing ECMO, and the prolonged duration of ECMO support in patients with COVID-19-related ARDS has revealed limitations in organization and resource utilization. Coordination of efforts at multiple levels, from research to implementation, resulted in numerous innovations in the delivery of ECMO.


Asunto(s)
COVID-19 , Oxigenación por Membrana Extracorpórea , Síndrome de Dificultad Respiratoria , Humanos , COVID-19/terapia , Oxigenación por Membrana Extracorpórea/métodos , Síndrome de Dificultad Respiratoria/etiología , Síndrome de Dificultad Respiratoria/terapia , Pandemias
11.
ASAIO J ; 69(3): 267-271, 2023 03 01.
Artículo en Inglés | MEDLINE | ID: covidwho-2258228

RESUMEN

During a 6 week period beginning early March 2020, 30 patients with severe coronavirus disease 2019 (COVID-19) were supported with venovenous extracorporeal membrane oxygenation (ECMO). This volume increase mandated rapidly training 116 nurses with no prior ECMO experience via a 2 hour crash course. A qualitative study using semistructured, in-depth interviews was conducted to evaluate the experiences of this unique nursing cohort. Fourteen registered nurses meeting inclusion criteria of no prior ECMO experience, attendance of ECMO educational crash course, direct assignment of COVID-19 patients requiring ECMO, and willingness to consent to recorded interviews participated in the study. Two semistructured interviews were conducted, audio recorded, and transcribed verbatim. Thematic analysis of the interviews was completed using Colaizzi's phenomenological method. Six themes identified were anxiety and fear of patient harm, isolation and depersonalization, value of didactic education with reinforced clinical experience, professional growth, importance of team collaboration, and pride and gratitude. Subthemes were additionally extracted. Nurses faced multiple obstacles during the pandemic. ECMO added a layer of complexity, as these patients required labor-intensive, high acuity nursing care. The impact of the pandemic and its unique challenges on nursing and medical staff warrants further investigation.


Asunto(s)
COVID-19 , Oxigenación por Membrana Extracorpórea , Humanos , Oxigenación por Membrana Extracorpórea/métodos , Pandemias
12.
J Extra Corpor Technol ; 54(3): 235-238, 2022 Sep.
Artículo en Inglés | MEDLINE | ID: covidwho-2227188

RESUMEN

COVID-19 morbidity and mortality are not equivalent to other etiologies of acute respiratory distress syndrome (ARDS) as fulminant activation of coagulation can occur, thereby resulting in widespread microvascular thrombosis and consumption of coagulation factors. A 53-year-old female presented to an emergency center on two occasions with progressive gastrointestinal and respiratory symptoms. She was diagnosed with COVID-19 pneumonia and admitted to a satellite intensive care unit with hypoxemic respiratory failure. She was intubated and mechanically ventilated, but her ARDS progressed over the next 48 hours. The patient was emergently cannulated for veno-venous extracorporeal membrane oxygenation (V-V ECMO) and transferred to our hospital. She was in profound shock requiring multiple vasopressors for hemodynamic support with worsening clinical status on arrival. On bedside echocardiography, she was found to have a massive pulmonary embolism with clot-in-transit visualized in the right atrium and right ventricular outflow tract. After a multidisciplinary discussion, systemic thrombolytic therapy was administered. The patient's hemodynamics improved and vasopressors were discontinued. This case illustrates the utility of bedside echocardiography in shock determination, the need for continued vigilance in the systematic evaluation of unstable patients in the intensive care unit, and the use of systemic thrombolytics during V-V ECMO in a novel disease process with evolving understanding.


Asunto(s)
COVID-19 , Oxigenación por Membrana Extracorpórea , Embolia Pulmonar , Síndrome de Dificultad Respiratoria , Trombosis , Humanos , Femenino , Persona de Mediana Edad , Oxigenación por Membrana Extracorpórea/métodos , COVID-19/complicaciones , COVID-19/terapia , Embolia Pulmonar/etiología , Embolia Pulmonar/terapia , Síndrome de Dificultad Respiratoria/etiología , Síndrome de Dificultad Respiratoria/terapia , Terapia Trombolítica
13.
PLoS One ; 18(1): e0280502, 2023.
Artículo en Inglés | MEDLINE | ID: covidwho-2214802

RESUMEN

BACKGROUND: Patients with COVID-19 and severe acute respiratory failure may require veno-venous extracorporeal membrane oxygenation (VV ECMO). Yet, this procedure is resource-intensive and high mortality rates have been reported. Thus, predictors for identifying patients who will benefit from VV ECMO would be helpful. METHODS: This retrospective study included 129 patients with COVID-19 and severe acute respiratory failure, who had received VV ECMO at the University Medical Center Regensburg, Germany, between 1 March 2020 and 31 December 2021. Patient-specific factors and relevant intensive-care parameters at the time of the decision to start VV ECMO were investigated regarding their value as predictors of patient survival. In addition, the intensive-care course of the first 10 days of VV ECMO was compared between survivors and patients who had died in the intensive care unit. RESULTS: The most important parameters for predicting outcome were patient age and platelet count, which differed significantly between survivors and non-survivors (age: 52.6±8.1 vs. 57.4±10.1 years, p<0.001; platelet count before VV ECMO: 321.3±132.2 vs. 262.0±121.0 /nL, p = 0.006; average on day 10: 199.2±88.0 vs. 147.1±57.9 /nL, p = 0.002). A linear regression model derived from parameters collected before the start of VV ECMO only included age and platelet count. Patients were divided into two groups by using receiver operating characteristics (ROC) analysis: group 1: 78% of patients, mortality 26%; group 2: 22% of patients, mortality 75%. A second linear regression model included average blood pH, minimum paO2, and average pump flow on day 10 of VV ECMO in addition to age and platelet count. The ROC curve resulted in two cut-off values and thus in three groups: group 1: 25% of patients, mortality 93%; group 2: 45% of patients, mortality 31%; group 3: 30% of patients, mortality 0%.


Asunto(s)
COVID-19 , Oxigenación por Membrana Extracorpórea , Síndrome de Dificultad Respiratoria , Insuficiencia Respiratoria , Humanos , Adulto , Persona de Mediana Edad , Oxigenación por Membrana Extracorpórea/métodos , Pronóstico , Estudios Retrospectivos , COVID-19/terapia , Cuidados Críticos , Insuficiencia Respiratoria/terapia
14.
Medicine (Baltimore) ; 100(30): e26798, 2021 Jul 30.
Artículo en Inglés | MEDLINE | ID: covidwho-2191047

RESUMEN

INTRODUCTION: Patients with coronavirus disease (COVID-19) may develop acute respiratory distress syndrome (ARDS). There have been few reports of postpartum woman with ARDS secondary to COVID-19 who required respiratory support using veno-venous extracorporeal membrane oxygenation (ECMO). We present the case of a 31-year-old woman who was admitted to hospital at 35 weeks gestation with ARDS secondary to COVID-19 and required ECMO during the postpartum period. PATIENT CONCERNS: The patient had obvious dyspnea, accompanied by chills and fever. Her dyspnea worsened and her arterial oxygen saturation decreased rapidly. DIAGNOSIS: ARDS secondary to COVID-19. INTERVENTIONS: Emergency bedside cesarean section. Medications included immunotherapy (thymosin α 1), antivirals (lopinavir/ritonavir and ribavirin), antibiotics (imipenem-cilastatin sodium and vancomycin), and methylprednisolone. Ventilatory support was provided using invasive mechanical ventilation. This was replaced by venous-venous ECMO 5 days postpartum. ECMO management focused on blood volume control, coagulation function adjustment, and airway management. OUTCOMES: The patient was successfully weaned for ECMO and the ventilator and made a good recovery. CONCLUSION: Special care, including blood volume control, coagulation function adjustment, and airway management, should be provided to postpartum patients with ARDS secondary to COVID-19 who require ECMO support.


Asunto(s)
COVID-19/complicaciones , Oxigenación por Membrana Extracorpórea , Periodo Posparto , Complicaciones Infecciosas del Embarazo/virología , Adulto , COVID-19/terapia , Cesárea , Oxigenación por Membrana Extracorpórea/métodos , Femenino , Humanos , Embarazo , Complicaciones Infecciosas del Embarazo/terapia
15.
Pol Merkur Lekarski ; 50(300): 337-341, 2022 Dec 22.
Artículo en Inglés | MEDLINE | ID: covidwho-2169555

RESUMEN

The course of COVID-19 with an incidence of 15-42% can be complicated by the development of acute respiratory distress syndrome (ARDS). The mortality rate with severe forms exceeds 60%, which sometimes requires extracorporeal methods of life support. AIM: The aim of this study was to analyse the therapeutic efficacy of V-V ECMO in patients with ARDS caused by SARS-CoV-2. MATERIALS AND METHODS: A retrospective analysis was performed in patients with acute lung injury caused by COVID-19 and treated with V-V ECMO within a period from February 2020 to May 2021 at the ECMO Center of the Heart Institute Ministry of Health of Ukraine. All patients had PCR testing for viral RNA particles using RT-PCR ELITe analyser. RESULTS: During this period, 7 cases reported of V-V ECMO for ARDS caused by COVID-19. Five of seven patients were urgently transferred to our ECMO Center from other medical institutions, while 2 patients were transferred to the hospital being already connected to ECMO, and one patient was connected to ECMO immediately after hospitalization. The most common ECMO complication was circuit thrombosis - 42.9% (3/7), which required oxygenator replacement - in 2 cases and circuit replacement - in 1 case. Three patients had bleeding at the cannulation site. ECMO mortality rate was 57.1% (4/ 7), while the 30-day mortality rate - 71.4% (5/7). CONCLUSIONS: In our case series, out of seven critically ill COVID-19 patients who required ECMO to maintain adequate oxygenation, inpatient mortality was observed in 71.4%.


Asunto(s)
COVID-19 , Oxigenación por Membrana Extracorpórea , Síndrome de Dificultad Respiratoria , Humanos , COVID-19/terapia , COVID-19/complicaciones , SARS-CoV-2 , Oxigenación por Membrana Extracorpórea/efectos adversos , Oxigenación por Membrana Extracorpórea/métodos , Estudios Retrospectivos , Pandemias , Síndrome de Dificultad Respiratoria/etiología , Síndrome de Dificultad Respiratoria/terapia
17.
J Heart Lung Transplant ; 41(11): 1547-1555, 2022 11.
Artículo en Inglés | MEDLINE | ID: covidwho-2178981

RESUMEN

The number of lung transplant procedures performed internationally is increasing but the donor organ pool is insufficient to meet demand and waiting list mortality is unacceptably high. As survival rates for patients with acute respiratory distress syndrome managed on extracorporeal life support (ECLS) have steadily improved, a potential role for ECLS to support critically ill patients awaiting a donor organ match has emerged. We explore the rapidly evolving landscape of ECLS as a bridge to lung transplantation with review of the patient selection criteria, predictors of survival, modes of pre and peri-transplant support, and the importance of a holistic multidisciplinary approach to care. Finally, we consider innovations that are envisaged to increase the accessibility, safety, and effectiveness of ECLS delivery for future lung transplant candidates.


Asunto(s)
Oxigenación por Membrana Extracorpórea , Trasplante de Pulmón , Síndrome de Dificultad Respiratoria , Humanos , Oxigenación por Membrana Extracorpórea/métodos , Estudios Retrospectivos , Listas de Espera
18.
Curr Opin Crit Care ; 28(6): 674-680, 2022 Dec 01.
Artículo en Inglés | MEDLINE | ID: covidwho-2152246

RESUMEN

PURPOSE OF REVIEW: Coronavirus disease 2019 (COVID-19) pandemic changed the way we had to approach hospital- and intensive care unit (ICU)-related resource management, especially for demanding techniques required for advanced support, including extracorporeal membrane oxygenation (ECMO). RECENT FINDINGS: Availability of ICU beds and ECMO machines widely varies around the world. In critical conditions, such a global pandemic, the establishment of contingency capacity tiers might help in defining to which conditions and subjects ECMO can be offered. A frequent reassessment of the resource saturation, possibly integrated within a regional healthcare coordination system, may be of help to triage the patients who most likely will benefit from advanced techniques, especially when capacities are limited. SUMMARY: Indications to ECMO during the pandemic should be fluid and may be adjusted over time. Candidacy of patients should follow the same prepandemic rules, taking into account the acute disease, the burden of any eventual comorbidity and the chances of a good quality of life after recovery; but the current capacity of healthcare system should also be considered, and frequently reassessed, possibly within a wide hub-and-spoke healthcare system. VIDEO ABSTRACT: http://links.lww.com/COCC/A43.


Asunto(s)
COVID-19 , Oxigenación por Membrana Extracorpórea , Humanos , COVID-19/terapia , Oxigenación por Membrana Extracorpórea/métodos , Triaje , SARS-CoV-2 , Selección de Paciente , Calidad de Vida
19.
Sci Rep ; 12(1): 20950, 2022 Dec 05.
Artículo en Inglés | MEDLINE | ID: covidwho-2151082

RESUMEN

Despite being vital in treating intensive-care patients with lung failure, especially COVID-19 patients, Veno-Venous Extra-Corporeal Membrane Oxygenation does not exploit its full potential, leaving ample room for improvement. The objective of this study is to determine the effect of cannula positioning and blood flow on the efficacy of Veno-Venous Extra-Corporeal Membrane Oxygenation, in particular in relationship with blood recirculation. We performed 98 computer simulations of blood flow and oxygen diffusion in a computerized-tomography-segmented right atrium and venae cavae for different positions of the returning and draining cannulae and ECMO flows of 3 L/min and [Formula: see text]. For each configuration we measured how effective Veno-Venous Extra-Corporeal Membrane Oxygenation is at delivering oxygen to the right ventricle and thus to the systemic circulation. The main finding is that VV-ECMO efficacy is largely affected by the ECMO flow (global peak blood saturation: [Formula: see text]; average inter-group saturation gain: 9 percentage points) but only scarcely by the positioning of the cannulae (mean saturation ± standard deviation for the 3 L/min case: [Formula: see text]; for the [Formula: see text] case: [Formula: see text]). An important secondary outcome is that recirculation, more intense with a higher ECMO flow, is less detrimental to the procedure than previously thought. The efficacy of current ECMO procedures is intrinsically limited and fine-tuning the positions of the cannulae, risking infections, offers very little gain. Setting a higher ECMO flow offers the biggest benefit despite mildly increasing blood recirculation.


Asunto(s)
COVID-19 , Oxigenación por Membrana Extracorpórea , Humanos , Cánula , Oxigenación por Membrana Extracorpórea/métodos , COVID-19/terapia , Hemodinámica/fisiología , Oxígeno
20.
Int J Artif Organs ; 46(2): 93-98, 2023 Feb.
Artículo en Inglés | MEDLINE | ID: covidwho-2162168

RESUMEN

OBJECTIVE: Assessment of the results of the ProtekDuo cannula applied for dedicated right ventricular support with oxygenator in ARDS secondary to COVID-19. METHODS: Systematic literature search in NHS library, Medline (Pubmed) and EMBASE using appropriate keywords as well as PICOS and PRISMA approach. RESULTS: Out of 285 publications found, 5 publications met the search criteria and were included in this review. A total of 194 patients with ARDS secondary to COVID-19 underwent ProtekDuo placement to establish a combination of respiratory [veno-venous extracorporeal membrane oxygenation (V-V ECMO)] and right ventricular support. Patients treated using the ProtekDuo cannula had survival rates between 59% and 89% throughout the five studies, and a significant survival benefit when compared to an invasive ventilation group or compared to dual site V-V ECMO or other double lumen ECMO cannulas. One study focused on extubation and discontinuation of ventilator support, which could be achieved in 100% of ProtekDuo patients. An association for reduced incidence of acute kidney injury (AKI) and use of continuous renal replacement therapy (CRRT) could be shown when the ProtekDuo was used. CONCLUSION: Only limited literature is available for the ProtekDuo in V-P ECMO configuration in the setting of COVID-19 ARDS and should be interpreted with caution. Data on the ProtekDuo is suggestive for lower rates of mortality, AKI and CRRT as compared to other respiratory support modalities.


Asunto(s)
Lesión Renal Aguda , COVID-19 , Oxigenación por Membrana Extracorpórea , Síndrome de Dificultad Respiratoria , Humanos , Oxigenación por Membrana Extracorpórea/métodos , Cánula , Lesión Renal Aguda/terapia , Síndrome de Dificultad Respiratoria/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA